Magdalena Kegel,  —

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

Articles by Magdalena Kegel

Weighing Myeloma Cells Could Predict Treatment Responses, MIT Study Shows

Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could help doctors choose the right drug for the right patient, the team argued in the article they published in the journal Nature Communications. The…

First Myeloma CAR T-cell Therapy Phase 2 Trial Opens Enrollment

The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma — Breakthrough Therapy Designation. Regulators at the European Medicines Agency (EMA) also acknowledged the potential of the treatment by granting it PRIME (PRIority MEdicines) eligibility. The…